Sitagliptin, a DPP-4 inhibitor, administered once- or twice-daily, provides substantial improvement in 24-hour glucose control in Japanese patients with type 2 diabetes mellitus (T2DM)

被引：0

作者：

Nonaka, Kenji

Tsubouchi, Hiroshi

Okuyama, Kotoba

Fukao, Yukako

Stein, Peter P.

机构：

来源：

DIABETES | 2007年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A540 / A540

页数：1

共 50 条

[21] Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
Liu, Dan
Jin, Biao
Chen, Wei
Yun, Peng
BMC PHARMACOLOGY & TOXICOLOGY, 2019, 20 (1):
[22] Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4
Pilon, Dominic
Durkin, Michael
Manceur, Ameur
Ghelerter, Isabelle
Lafeuille, Marie-Hel
Lefebvre, Patrick
DIABETES, 2020, 69
[23] Effect of Sitagliptin on 24-Hour Glycemic Variations in Japanese Patients with Type 2 Diabetes as Assessed by Continuous Glucose Monitoring (CGM)
Taniguchi, Yukiko
Mori, Yutaka
Matsuura, Kenichi
Itoh, Yohta
Sezaki, Kazunori
Yokoyama, Junichi
Tajima, Naoko
DIABETES, 2010, 59 : A558 - A558
[24] Whole 24-hour continuous glucose monitoring (CGM) profiles with insulin glargine or oral antidiabetic drug (OAD) therapy in patients with type 2 diabetes mellitus (T2DM)
Yale, Jean-Francois
Harris, Stewart
Stewart, John
Gerstein, Hertzel C.
DIABETES, 2008, 57 : A118 - A118
[25] Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data
Miwa, Tetsuya
Yoshida, Shiori
Nakajima, Akihiro
Koto, Ruriko
Nishimura, Rimei
DIABETOLOGY INTERNATIONAL, 2024, 15 (03) : 483 - 494
[26] Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
Katsuno, Tomoyuki
Ikeda, Hiroki
Namba, Mitsuyoshi
DIABETES THERAPY, 2016, 7 (02) : 309 - 320
[27] Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
Tomoyuki Katsuno
Hiroki Ikeda
Mitsuyoshi Namba
Diabetes Therapy, 2016, 7 : 309 - 320
[28] Assessing nutritional information in adolescents with type 1 and type 2 diabetes mellitus (T1 and T2DM) using a 24-hour recall method
Balliet, Jessica
Deboard, Renee
Maglio, Kelly
Smith, Amber
Fitzgerald, Christopher
Kaugars, Astrida
Alemzadeh, Ramin
Kichler, Jessica
DIABETES, 2008, 57 : A468 - A468
[29] Efficacy and safety of alogliptin, a potent and highly selective DPP-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
Seino, Y.
Kaku, K.
DIABETOLOGIA, 2010, 53
[30] Evaluatin once- and twice-daily self-monitored blood glucose testing strategies for stable insulin-treated patients with type 2 diabetes
Hoffman, RM
Shah, JH
Wendel, CS
Duckworth, WC
Adam, KD
Bokhari, SU
Dalton, C
Murata, GH
DIABETES CARE, 2002, 25 (10) : 1744 - 1748

← 1 2 3 4 5 →